ERBB2 and mucinous adenocarcinoma: While high level amplification of ERBB2 was evident in the IDP and DCIS components, the mucinous carcinoma component showed only a low level gain of ERBB2 (validated by SISH), and an additional 13q loss (Supplementary Fig. 10).